---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-025901"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T17:20:18.539297+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Acura Pharma gets $300K more loans from AD Pharma, warns of possible shutdown if no financing by March 2026

## Summary
- Received $100,000 loans on Feb 6, Feb 13, and Mar 9, 2026 from Abuse Deterrent Pharma, LLC (AD Pharma), increasing principal balance to $9,894,279.
- Note bears interest at 5.25% per annum, with overdue amounts accruing at 7.5%; events of default include bankruptcy, payment failure, and admitted inability to pay debts.
- AD Pharma directly owns approximately 65% of Acura's outstanding common stock as of Feb 28, 2026, and is controlled by Mr. Schutte.
- If additional financing is not secured by end of March 2026, Acura will need to scale back operations, including furloughs and layoffs, or terminate operations and seek bankruptcy protection.
- No assurance of receiving more funds; failure could result in complete loss of shareholder value.

## SEC filing metadata
- accession: 0001104659-26-025901
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465926025901/0001104659-26-025901-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465926025901/tm268475d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-025901
- JSON: https://secwatch.observer/filing/0001104659-26-025901.json
- Plain text: https://secwatch.observer/filing/0001104659-26-025901.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC incurred loan of $100,000 with Abuse Deterrent Pharma, LLC at 5.25%.
  - Instrument: loan
  - Principal: $100,000
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Rate: 5.25%
  - Event: incurrence
  source text: On each of February 6, 2026, February 13, 2026 and March 9, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465926025901/0001104659-26-025901-index.htm
- Material Agreements
  ACURA PHARMACEUTICALS, INC entered into Note with Abuse Deterrent Pharma, LLC valued at $100,000 (effective 2026-02-06).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Value: $100,000
  - Effective: 2026-02-06
  source text: On each of February 6, 2026, February 13, 2026 and March 9, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC ("AD Pharma").
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465926025901/0001104659-26-025901-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.